Tartrate-resistant Acid Phosphatase Isoform 5b as Serum Marker for Osteoclastic Activity
Open Access
- 1 January 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (1) , 74-80
- https://doi.org/10.1093/clinchem/47.1.74
Abstract
Background: Tartrate-resistant acid phosphatase (AcP) 5b is a marker of osteoclastic activity and bone resorption. Immunoassays for serum TRAcP may lack sensitivity and specificity because of the presence of non-bone isoform 5a. The purpose of this study was to isolate the serum isoforms, quantify their disease-related expressions, and test an improved immunoassay for TRAcP 5b. Methods: We separated TRAcP isoforms chromatographically from pooled sera of healthy, rheumatoid arthritis (RA) and endstage renal disease (ESRD) subjects. TRAcP isoforms were identified by electrophoresis and quantified by biochemical and immunochemical assays. Serum TRAcP activity in healthy, RA, and ESRD cohorts was assessed at pH 5.5 and 6.1, and compared with bone alkaline phosphatase (BAP) and N-telopeptides of type I collagen (NTx). Results: TRAcP isoforms 5a and 5b were present in all sera; 5b was identical to osteoclastic TRAcP. In serum from healthy subjects, 5a accounted for 87% of the enzyme protein but only 55% of the activity. In RA, both isoforms were increased two- to threefold in protein, but their specific activities were subnormal. In ESRD, only 5b was abnormal, being increased fivefold in protein and threefold in activity. In RA sera, TRAcP activity did not correlate with either BAP or NTx. In ESRD sera, TRAcP activity correlated with BAP and NTx only when measured at pH 6.1. Conclusions: All sera contained both TRAcP isoforms 5a and 5b, but only 5b was present in bone. TRAcP isoform expression was variable in different diseases. Measurement of TRAcP activity at pH 6.1 improves the specificity of immunoassay for isoform 5b.Keywords
This publication has 32 references indexed in Scilit:
- Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Circulating biochemical markers of bone remodeling in uremic patientsKidney International, 1999
- Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary IndicesJournal of Bone and Mineral Research, 1999
- Two‐Site Immunoassays for Osteoclastic Tartrate‐Resistant Acid Phosphatase Based on Characterization of Six Monoclonal AntibodiesJournal of Bone and Mineral Research, 1999
- Characterization of Serum Tartrate-Resistant Acid Phosphatase and Development of a Direct Two-Site ImmunoassayJournal of Bone and Mineral Research, 1998
- Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?Arthritis & Rheumatism, 1997
- Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnoverScandinavian Journal of Clinical and Laboratory Investigation, 1991
- Development of an Immunoassay for Human Serum Osteoclastic Tartrate-Resistant Acid Phosphatase*Journal of Clinical Endocrinology & Metabolism, 1990
- Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidismClinica Chimica Acta; International Journal of Clinical Chemistry, 1983
- Clinical significance of the human acid phosphatasesThe American Journal of Medicine, 1974